Chemokine Therapeutics to present phase 1 study results on cancer blocker

By Lisa Kerner

Erie, Pa., Jan. 17 - Chemokine Therapeutics Corp. has completed a phase 1, dose-escalation clinical trial using CTCE-9908 in healthy volunteers. The completed single-dose phase 1 clinical trial demonstrated CTCE-9908, designed to block the spread of cancer, to be safe and well tolerated by the study subjects.

Research has already demonstrated that the chemokine SDF-1 is critical for both the migration and attachment of cancer cells to normal tissue and the formation of new blood vessels needed to provide nutrients to cancer cells, according to a company news release. Chemokines are one of the major mediators of stem cell activity including stem cell growth, differentiation and maturation.

Chemokine Therapeutics has designed CTCE-9908, an inhibitor of SDF-1, to block the spread of certain common cancers by inhibiting their metastasis and growth.

"Successful treatment of cancer requires both prevention of tumor migration and blockage of tumor blood supply," Hassan Salari, Chemokine Therapeutics' president and chief executive officer, stated in the release. "This can provide a powerful approach to the management of cancer. There are very few drugs that have such properties; therefore we are hopeful that CTCE-9908 may be able to address these needs."

The company will present its study results at the 2006 Miami Biotechnology Winter Conference on Angiogenesis in Cancer and Vascular Disease in February.

A phase 1b/2 clinical trial, designed to explore early signs of efficacy after repeat administration of CTCE-9908 in a late-stage cancer, is planned for the first quarter of this year.

Chemokine Therapeutics, based in Vancouver, B.C., is a biotechnology company specializing in the therapeutic potential of stem cells through chemokine pathways.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.